COPENHAGEN, Denmark, Dec. 8, 2008 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Genmab A/S (NasdaqGS:GEN - News) announced today positive results from a pivotal trial pre-planned interim analysis of Arzerra(TM) (ofatumumab) in the treatment of refractory chronic lymphocytic leukaemia (CLL). The results demonstrate the potential of ofatumumab as a new treatment option for heavily pre-treated patients with CLL who do not respond to, or are ineligible for currently available treatment options (1). This research is being presented at the 50th Annual Meeting of the American Society of Hematology, 6-9 December, 2008. Ofatumumab is an investigational drug that has not been approved for any indication in any market at this time.
